Unique long term drug efficacy studies with the 3D CoSeedis™ Tumor Relapse Assay

Long term efficacy of drugs is an important parameter to correctly determine the dosage and the duration of a certain treatment. This is particularly true for anti-cancer drugs where tumor relapse caused by drug-resistant dormant tumor cells is an often observed phenomenon. Killing quiescent tumor cells is therefore crucial for successful cancer treatment. Testing and optimizing treatment to this aim has so far been difficult, however. Not any longer, though!
Tumor cells were seeded into 3D CoSeedis™ Chip880. After 2 days, the aggregated micro-tumors were treated for 5 days with drug 1 or drug 1 opt, respectively. Subsequently, micro-tumors were transferred into growth medium without drug and tumor volume was measured using the 3D CoSeedis™ volumetric analysis protocol. Each data point represents the average volume of 400 micro-tumors grown under identical conditions. Drug 1 induced initial growth arrest (arrows) for 4 days before recovery and relapse occured. The optimized drug (drug 1 opt), however, did not show tumor recovery and micro-tumor growth was arrested permanently.
abc biopply has developed the unique and novel 3D CoSeedis™ Tumor Relapse Assay to address precisely long term effects of anti-cancer compounds on tumor relapse.
The assay performance is characterized by: 
  • Data collection of 400 micro-tumors per treatment and time point
    ⇨ statistical accuracy to identify stochastic and rare relapse events
  • Unique cell culture features of 3D CoSeedis™ technology enable long term studies ⇒ identification of late relapse tumors
  • Modular stet-up of the assay for increased testing flexibility ⇨ fast and accurate optimization of various treatment protocols
  • Integral part of abc biopply’s cancer compound test services
The 3D CoSeedis™ Tumor Relapse Assay is part of abc biopply’s compound test service. However, the assay can also be licensed for in-house applications. Contact me to get a list of our license options and the included support packages.
Interested? I am looking forward to answering your phone call.


   Best regards

   Marco Leu, PhD
   Sales & Operation
   abc biopply ag

   Direct Email / Phone +41 (0)79 834 95 56

 Back to overview

Contact us